Projectes destacats

  • A phase II trial of cabozantinib for patients with hepatocellular carcinoma in sorafenib intolerant (ACTION trial)

    Investigador/a principal: María Reig Monzón.
    Finançador: Investigator Initiated .
    Codi: CP042633.
    Durada: 25/03/2019
  • A multicentrer phase II study of Regorafenib followed by Nivolumab in patients with Hepatocellular Carcinoma after first-line treatment (GOING trial)

    Investigador/a principal: María Reig Monzón.
    Finançador: Fundació Clínic per a la Recerca Biomèdica. .
    Durada: 12/03/2019 - 30/06/2024
  • Importancia del inflamasoma en la sensibilidad o resistencia a los inhibidores tirosina quinasa en pacientes con cáncer de hígado (PI18/00358) ( Importance of the inflammasome in the sensitivity or resistance to tyrosine kinase inhibitors in patients with

    Investigador/a principal: María Reig Monzón.
    Finançador: Instituto de Salud Carlos III .
    Durada: 01/01/2019 - 31/12/2022
  • A phase I open label, clinical trial evaluating the safety and anti-tumor activity of autologous T cells expressing enhanced TCRS specific for alpha-fetoprotein (AFP C332T) in HLA-A2 positive subjects with advanced hepatocellular carcinoma (HCC).

    Investigador/a principal: Jordi Bruix Tudo.
    Finançador: Adaptimmune .
    Codi: ADP-0033-001.
    Durada: 01/01/2018 - 31/12/2033
  • Multicenter, open label single arm safety study and the antitumor efficacy of Nivolumab after Selective Internal Radiation Therapy (SIRT) using SIR-Spheres for the treatment of patients with hepatocellular carcinoma that are candidates for locoregional th

    Investigador/a principal: María Reig Monzón.
    Finançador: Clínica Universitaria de Navarra .
    Durada: 01/01/2018
  • Analysis of potential changes in antitumor immune activity in patients with hepatocellular carcinoma after C virus erradication with direct antiviral agents (GLD/00095)

    Investigador/a principal: María Reig Monzón.
    Finançador: Gilead Sciences, S.L .
    Durada: 01/01/2017 - 01/01/2019